a new era of regenerative medicine

I think we will soon start hearing a lot more about this rapidly growing market of tissue engineering:

Imo, Twiggy and friends would also have more interest in BioMD than simply an opportunity for Allied to be trading on the asx.

"The lack of tissue and organs available for transplantation, as well as the problems associated with their transplantation such as donor site morbidity, immune rejection, and pathogen transfer, led to the emergence of the discipline of tissue engineering. The ultimate goal of tissue engineering as a treatment concept is to replace and even recover the anatomic structures and functions of the damaged, injured, or missing tissue and organs.

Tissue engineering is an advanced stage of biomaterials science as well. The big improvement of tissue engineering from traditional biomaterials science is that tissue engineering is the combination of both artificial compo-nents (i.e. biomaterials) and biological components (i.e. cells, tissues, and biomolecules) to create analogues of normal tissue and organs. In contrast, tra-ditional biomaterial science uses only artificial constructs to replace part of the normal functions of tissue and organs, rather than their anatomical structures. Therefore, tissue engineering requires various components including:

- regeneration-component cells.
- carriers or support scaffolds.
- growth factors.
- dynamic forces.

Tissue engineering as a discipline is very young and still in the early developmental stage.

Surprisingly, after only approximately four decades of growth, the field of tissue engineering is no longer limited to the academic laboratory but is rapidly growing in industry as well. For example, tissue-engineered skin is already available on market shelves in many countries including the United States and the United Kingdom. Tissue-engineered cartilage, temporary liver-assistance devices, and tissue-engineered pancreas are all in clinical trials." Click here for Babylon Uni research paper 24/05/2011

Perhap this explains why we've increased from 25 to over 65% interest in Allied now? Something in the air smells fresh to me ;)

With such a tightly held register and good exposure to cash-up Allied investors this thing is bound to fly when news finally arrives.

I enjoyed reading this following in the most recent bioshares report:

"The third piece of the puzzle is funding. Allied Medical has 2200 shareholders with many also on the Fortescue register and Andrew Forrest owning 46% of Allied Medical. Presumably if the company has reached sufficient proof of concept with one of its technologies, then there is the opportunity to go to its shareholder base to bring those technologies to market.

One of the impediments and failures of the biotech industry is an inability to access the end user, which is often controlled by multinational pharmaceutical or medical device companies. Allied Medical is potentially in a position to solve that distribution hurdle similar to what Fortescue had to achieve in building its rail link to ship its iron ore.

There are synergies and benefits for both groups. Allied currently sells products to cardiologists with whom it has excellent relationships, according CEO Lee Rodne. BioMD's first product, the CardioCel patch, will be sold to cardiologists. BioMD will seek to list the product with the TGA this year that will allow it to launch that product.

For Allied, a merger with BioMD represents a way to gain a public listing on the ASX, and from there improved access to capital markets. Both groups will benefit from an increased size in attracting capital to fund programs". Click here for the Bioshare Report